A US company seeking to use MDMA capsules to treat post-traumatic stress disorder has said federal regulators rejected the bid. Lykos Therapeutics said the FDA requested an additional Phase 3 trial to gather more data.
Source link : https://www.dw.com/en/us-fda-says-no-to-psychedelic-mdma-as-ptsd-treatment/a-69905240?maca=en-rss-en-all-1573-rdf
Author :
Publish date : 2024-08-10 00:05:00
Copyright for syndicated content belongs to the linked Source.